A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel-group Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Biomarkers of AZD3839 Including an Open-label Food Effect Group in Healthy Male and Female Volunteers of Non-childbearing Potential.

Trial Profile

A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel-group Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Biomarkers of AZD3839 Including an Open-label Food Effect Group in Healthy Male and Female Volunteers of Non-childbearing Potential.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jan 2014

At a glance

  • Drugs AZD 3839 (Primary)
  • Indications Alzheimer's disease; Dementia
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Apr 2012 Actual patient number added 72 according to ClinicalTrials.gov.
    • 05 Apr 2012 Actual end date (June 2011) added as reported by ClinicalTrials.gov.
    • 05 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top